Clinical Trial Update: Golimumab in Ulcerative Colitis (UC) Patients With Loss of Response (LOR) Followed by Dose Optimization [Phase 2]

View source ↗

Summary

Phase 2 trial updating golimumab in ulcerative colitis patients with loss of response followed by dose optimization has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Golimumab (golimumab)

Snippet

Sponsor: Centre Hospitalier Universitaire de Saint Etienne | Conditions: Ulcerative Colitis | Phase 2 | Status: COMPLETED